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metastasesAbstract Introduction: Patients with non-small cell lung cancer (NSCLC) experience lepto-
meningeal metastases (LM) in 3e9% of cases. Because overall survival (OS) and performance
status are very poor, they are mostly excluded from clinical trials. Here, we evaluated survival
of patients with NSCLC having LM treated with immune checkpoint inhibitors (ICIs).
Methods: A prospectively collected list of patients with advanced NSCLC treated with ICIs
between November 2012 and July 2018 in 7 European centres was merged. All patients with
LM before ICI start were selected, data were retrospectively added and patients were classified
according to the National Comprehensive Cancer Network (NCCN) LM prognostic classifi-
cation (good/poor). Progression-free survival (PFS) and OS on ICIs were evaluated.
Results: Nineteen of 1288 (1.5%) patients had LM; 73.7% had synchronous brain metastases;
73.7% had neurological symptoms at the start of ICIs and 52.6% were in the NCCN LM good
prognosis group. Programmed death ligand-1 (PD-L1) expression was known for 42.1% of pa-
tients (87.5% positive). Median follow-up was 13 months from the start of ICIs, and median
(95% confidence interval [CI]) PFS on ICIs was 2.0 (1.8e2.2) months. Six-month PFS rate was
21.0% and was significantly higher in the NCCN good versus poor prognostic group: 40% vs
0% (p Z 0.05). Twelve-month PFS rate was 0%. Median (95% CI) OS from the start of ICIs
was 3.7 (0.9e6.6) months. Six-month OS rate was 36.8%, and 12-month OS rate was 21.1%;
both were not statistically significantly different for the good versus poor NCCN prognostic
group (p Z 0.40 and p Z 0.56, respectively).
Conclusion: Some patients with NSCLC having LM do benefit from ICI treatment; specif-
ically, those in the NCCN LM good prognosis group can obtain a long survival.
ª 2019 Elsevier Ltd. All rights reserved.1. Introduction
Leptomeningeal metastases (LM) are diagnosed in up
to 9% of patients with non-small cell lung cancer
(NSCLC) [1,2]. Diagnosis is based on clinical evalu-
ation, typical findings on brain/spinal cord magnetic
resonance imaging (MRI) and presence of tumour
cells in the cerebrospinal fluid (CSF) [3,4]. The Na-
tional Comprehensive Cancer Network (NCCN)
guideline advises to classify patients according to
poor or good risk (Supplemental Table 1) and rec-
ommends best supportive care (BSC) for the poor
risk group [3]. The European Association of Neuro-
Oncology (EANO)eEuropean Society for Medical
Oncology (ESMO) guideline advises BSC in those
with an expected survival of less than one month [4].
Treatment for patients with better prognosis consists
of (combinations of) radiotherapy and systemic
therapy with/without intrathecal chemotherapy [3,4].
Despite treatment, the median overall survival (OS) is
1e3 months for patients without, and up to 12
months for patients with, a targetable molecular
alteration [5,6]. Immune checkpoint inhibitor (ICI)
therapy has revolutionised the treatment for patients
with NSCLC and has become standard of care in
locally advanced and metastatic disease [7,8]. How-
ever, all NSCLC ICI trials have excluded patients
with LM; hence, only a few case reports are available
[9,10]. Two phase II trials included patients with only
melanoma or mainly breast cancer [11,12]. To obtainmore data on survival of patients with NSCLC
having LM treated by ICI therapy, we performed a
multicenter data collection.
2. Patients and methods
A prospectively collected list of patients with advanced
NSCLC treated with ICIs between November 2012 and
July 2018 in seven European centres (five French and
two Dutch) was merged. All consecutive patients with
advanced NSCLC were included when they were treated
with programmed death ligand-1 (PD-L1) inhibitors
with or without antiecytotoxic T-lymphocyte antigen-4
(CTLA4) within routine clinical care, expanded access/
compassionate use programs and clinical trials. Medical
records were screened, and all patients diagnosed with
LM (based on positive CSF analysis and/or imaging)
before the start of ICIs were included. LM were classi-
fied according to EANO-ESMO criteria (Supplemental
Table 2) [4].
Demographics, clinical, pathological/molecular and
survival data were retrospectively extracted from the
medical records between October 2018 and December
2018. PD-L1 expression was assessed on tumour cells by
immunohistochemistry in each local institution.
Expression of at least 1% was considered positive.
Radiological assessments of the brain and extracranial
disease were performed at discretion of the treating
physician (usually every six to nine weeks), and response
was determined locally at each institution by the
L.E.L. Hendriks et al. / European Journal of Cancer 116 (2019) 182e189184investigator. Patients were classified as poor or good
prognosis according to the NCCN criteria
(Supplemental Table 1) [3].
This study was approved by the Institutional Review
Board of Gustave Roussy (Commission Scientifique des
Essais Thérapeutiques) and the ethical committee of
Maastricht University Medical Centerþ (number
2018e0805): informed consent was considered not
necessary by the ethics committee.
2.1. Statistical analysis
OS was calculated from the date of the first ICI
administration until death due to any cause. Progres-
sion-free survival (PFS) was calculated from the date of
the first ICI administration until progressive disease
(PD: cranial and/or extracranial or symptomatic when
imaging was not available), or death due to any cause.
Statistics were performed using SPSS (IBM statistics,
version 23). Descriptive statistics of demographic and
clinical variables were obtained. Six- and 12-month PFS
and OS rates were compared for different groups using
the Fisher exact test. Survival curves were estimated
using the KaplaneMeier method.
3. Results
3.1. Patient selection and characteristics of patients with
leptomeningeal metastases
Data of 1288 patients with NSCLC treated with ICIs
were screened. Nineteen (1.5%) had LM (with/withoutTable 1
Patient characteristics.
Nr Age at the
start of ICI
therapy, years
Gender Smoking
status/PY
Histology/molecular
status
PD-L
status
1 68.1 F Former/40 SCC/unk unk
2 65.8 F Former/35 AC/KRAS 20%/2
3 53.6 M Former/35 AC/KRAS unk
4 63.5 F Unk/unk AC/KRAS 80%/2
5 69.1 M Former/20 AC/ALK unk
6 52.0 F Former/7 AC/EGFR 0/unk
7 55.3 F Unk/unk AC/EGFR Pos/2
8 55.3 F Current/30 AC/KRAS unk
9 51.0 F Former/15 AC/MET 80%/2
10 41.1 M Former/15 AC/WT unk
11 66.4 F Former/50 AC/WT 95%/2
12 65.4 M Former/unk AC/WT 90%/2
13 56.8 F Current/40 AC/WT unk
14 69.1 F Never AC/EGFR unk
15 66.0 F Former/unk AC/WT unk
16 52.2 F Current/unk AC, WT unk
17 53.6 F Current/20 AC/BRAF 80%/u
18 57.2 M Current/40 SCC/unk unk
19 64.8 M Current/35 AC/EGFRampl unk
Abbreviations: nr: number; ICI: immune checkpoint inhibitor; PY: packy
squamous cell carcinoma; AC: adenocarcinoma; KRAS: Kirsten rat sarco
RAF murine sarcoma viral oncogene homologue B; ampl: amplification; ubrain metastases) at the start of ICI therapy (Table 1):
mean age was 59.3 years (range, 41.1e69.1), 13 (68.4%)
were female, 17 (89.5%) had adenocarcinoma and eight
(42.1%) had known PD-L1 status (7/8 positive, PD-L1
expression level: 20e95%). Six patients had a target-
able driver mutation (3 EGFR, 1 ALK, 1 BRAF, 2
MET); all these patients received ICI after exhaustion of
targeted therapies. Fourteen (73.7%) patients had brain
metastases also, and 14 (73.7%) had neurological
symptoms at the start of ICI therapy (varying from
slight headache to severe neurological symptoms). Ten
out of 19 (52.6%) were in the good prognostic NCCN
LM group. Details on LM diagnosis, treatment and
symptoms and PFS/OS per patient are depicted in Table
2. Patient 3 (also reported previously) [10] was treated
with intrathecal methotrexate before the start of ICIs,
and patient 17 received intrathecal methotrexate con-
current with nivolumab.3.2. Outcome
Time from LM diagnosis to the start of ICI therapy
ranged from 0 to 16.6 months: for five and eight pa-
tients, respectively, LM diagnosis was within one and 
six months of the start of ICI therapy (Fig. 1). Median
follow-up from the start of ICI therapy was 13 months.
Except for one patient (patient 13, died of trauma), all
patients showed disease progression. The clinical con-
dition of three patients deteriorated very rapidly; they
died before brain or extracranial imaging could be per-
formed. For one patient, the neurological condition
improved, nine deteriorated (Table 2). Seven patients1
/antibody
Nr of organs
with metastases at
the start of ICI therapy
ICI treatment
line
Type of ICI
3 3 Nivolumab
8 2 3 Pembrolizumab
3 2 Nivolumab
2C3 3 2 Pembrolizumab
3 4 Nivolumab
5 4 Nivolumab
2C3 3 5 Pembrolizumab
6 2 Nivolumab
8 2 5 Pembrolizumab
4 3 Nivolumab
2C3 4 2 Pembrolizumab
8 2 2 Pembrolizumab
3 2 Nivolumab
3 7 Nivolumab
6 2 Nivolumab
5 2 Nivolumab
nk 3 3 Nivolumab
5 2 Nivolumab
7 6 Nivolumab
ears; PD-L1: programmed death ligand-1; F: female; M: male; SCC:
ma viral antigen; EGFR: epidermal growth factor receptor; BRAF: v-
nk: unknown.
Table 2
Leptomeningeal metastases details and PFS and OS from immune checkpoint inhibitor initiation per patient.
Nr LP/results MRI
braina
EANO-ESMO
diagnosis group
BM at the
start of ICI
therapy
Cranial
rtx before
ICI
Time from
cranial
rtx to ICI,
months
Time from
LM diagnosis
to the start of
ICI therapy,
months
KPS at
the start
of ICI
therapy
MRI brain
baseline
ICI/follow-u
ICI
symptomatic at
start of ICI
rapy/symptoms
Use of
steroids/dose
prednisolone
per day
NCCN
risk
group
Neurological
status during
ICI
ICI PFS,
months
ICI OS,
monthsb
1 No Yes IIB probable No Yes 0.5 1.2 100 Yes/yes No Good Stable 10.4 11.6þ
2 Yes/neg Yes IIB probable No No N/A 16.6 80 No/yes s/visual
turbances
Yes/10 mg Good Stable 7.3 13.0þ
3 Yes/pos Yes 1 A Yes No N/A 8.5 80 Yes/no s/facialis paralysis Yes/20 mg Good Improve 6.4 10.7
4 No No
(PET-CT)
IIunk probable Yes Yes 18.9 (BM) 15.8 90 Yes/no s/headache No Good Stable 6.1 12.9þ
5 Yes/pos Yes IC No No N/A 2.3 80 Yes/no s/light headache,
tigo
No Good Worse 2.8 3.7
6 Yes/neg Yes IIB probable Yes Yes 5.6 (BM) 4.0 70 No/no s/visual
turbances,
usea, vomiting
No Poor Stable 2.5 10.6
7 Yes/neg Yes IIB probable Yes No N/A 0..2 90 Yes/no s/sensory
turbances upper
remities
No Good Stable 2.1 15.6
8 No Yes IIA probable Yes Yes 0 0.1 60 Yes/no s/headache,
usea
Yes/unk Poor Worse 2.0 2.0
9 Yes/pos Yes IA Yes Yes 1.6 1.6 80 Yes/no s/sensory loss
s, pain legs
Yes/20 mg Good Worse 1.9d 2.0
10 Yes/pos Yes IB Yes Yes 5.5 7.6 50 Yes/no s/visual
turbances,
sartria, absences
Yes/80 mg Poor Worse 1.8 2.5
11 No Yes IIA probable Yes Yes 5.5 6.0 80 Yes/no s/light headache Yes/1.5 mg Good Stable 1.8 4.0
12 Yes/pos Yes IB Yes Yes 1.2 6.1 80 No/no s/headache,
miting, hearing
s, walking
blems
Yes/100 mg Poor Worse 1.7d 1.8
13 No Yes IIB probable Yes Yes 0.1 0.1 60 Yes/yes s/facialis
ralysis, headache,
ebellar symptoms
No Poor Stable 1.7 1.7e
14 No Yes IIB probable Yes Yes 9.1 (BM) 1.2 70 Yes/yes Yes/40 mg Good Worse 1.7 5.8
15 No Yes IIA probable Yes Yes 0.7 1.3 70 No/no s/severe headache No Poor Worse 0.9 1.7
16 No Yes IIC probable Yes Yes 12.0 12.5 60 Yes/no No Poor Stable 0.8d 0..9
(continued on next page)
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L.E.L. Hendriks et al. / European Journal of Cancer 116 (2019) 182e189186had baseline and follow-up brain imaging (five had MRI
follow-up): three had progressive central nervous system
disease (PD) as the best cranial response (two stable
disease (SD) extracranial and 1 PD extracranial) and 2
SD. The two patients with SD as the best LM response
did not experience LM PD on MRI during follow-up
but had extracranial PD.
Median (95% confidence interval [CI]) PFS on ICIs
was 2.0 (1.8e2.2) months. Six-month PFS rate was 21.0%
(4/19 patients, 95% CI: 1e41%) and was significantly
higher for the NCCN LM good versus poor prognostic
group (40% [95% CI: 3e77%] vs 0% [95% CI: not evalu-
able (NE)], p Z 0.05). Twelve-month PFS rate was 0%.
Survival curves are depicted inFig. 2A. Five patients were
treated with ICIs for six months, four of whom were in
the good prognostic group. None of the patients treated
with  six months of ICIs had a targetable driver muta-
tion. PD-L1 status was known only for two (20% and
80%, respectively). The five others who were PD-L1
positive all progressed within 0.7e2 months.
Except for three patients, all died. Median OS from
LM diagnosis was 10.0 (95% CI: 5.6e14.3) months.
Median OS from the start of ICI therapy was 3.7 (95%
CI: 0.9e6.6) months (Fig. 2B). Six-month OS from the
start of ICI therapy was 36.8% (7/19 patients, 95% CI:
13e61%), and 12-month OS was 21.1% (4/19 patients,
95% CI: 1e41%); both were not statistically significantly
different for the poor versus good NCCN prognostic
group (p Z 0.22 and p Z 0.33, respectively). Two out of
four patients with 12-month survival had a PFS on
ICI therapy for 6 months; three were PD-L1 positive
(other unknown). Three received another line of sys-
temic treatment.4. Discussion
Data on survival of patients with NSCLC having LM
treated with ICIs are scarce. To the best of our
knowledge, with 19 included patients, we report here
the largest, detailed multicentre series to date. Because
ICI efficacy is so far unknown for LM, most of them
received ICIs when alternatives were no longer avail-
able. In general, survival was poor, although some
patients, especially those with an NCCN good prog-
nosis classification, benefited from ICI treatment (6-
month PFS 21.0%, 40% versus 0% for good versus poor
prognosis classification). Furthermore, some patients
with LM can obtain a relatively long survival (also after
PD on ICI therapy) because 6- and 12-month OS rates
were 36.8% and 21.1%, respectively. The median OS
was comparable to a single-arm phase II pem-
brolizumab trial, including 20 patients with LM (1
NSCLC; 3.7 vs 3.6 months), but 6-month (22.0%) and
12-month OS (0%) rates were lower than our data [11].
Compared with our data, a similar median (5.1
months), six- (43.8%) and 12-month (31.3%) OS rates
Fig. 1. Swimmer plot of patients with NSCLC having leptomeningeal metastases treated with immune checkpoint inhibitors. Abbrevi-
ations: PD-L1: programmed death-ligand 1; NCCN: National Comprehensive Cancer Network; LM: leptomeningeal metastases; SCC:
squamous cell carcinoma; unk: unknown; AC: adenocarcinoma; KRAS: Kirsten rat sarcoma viral antigen mutation; beva: bevacizumab;
carbo: carboplatin; TKI: tyrosine kinase inhibitor; ALK: anaplastic lymphoma kinase translocation; nav: navelbin; m: months; EGFR:
epidermal growth factor receptor mutation; WT: wild type; BRAF: v-raf murine sarcoma viral oncogene homologue B; amp: amplifi-
cation; ICI: immune checkpoint inhibitor; tx: therapy; BSC: best supportive care; PD: progressive disease; NE: not evaluable.
Fig. 2. (A) Progression-free survival on immune checkpoint inhibitor therapy; (B) overall survival from the start of immune checkpoint
inhibitor therapy. Abbreviations: NCCN: National Comprehensive Cancer Network; LM: leptomeningeal metastases; PFS: progression-
free survival; ICI: immune checkpoint inhibitor; OS: overall survival.
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cohort with progressing and/or symptomatic brain
metastases, and/or LM [12]. A retrospective series
including 25 patients with melanoma having LM, 10 of
whom were treated with the CTLA4 inhibitoripilimumab, showed survivals from diagnosis of LM
ranging from 1.4 to 54.2 months for patients treated
with ipilimumab (ipilimumab treatment was often
preceded or followed by BRAF-inhibition and/or
whole brain radiotherapy (WBRT)) [13].
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of ICI therapy and only five patients underwent follow-
up brain MRI during ICI treatment, differentiation be-
tween ICI toxicity and brain/LM progression was diffi-
cult. In the phase II trials reported to date with mainly
patients with breast cancer and melanoma, toxicity was
usually low grade and manageable. Headache was the
most common neurological grade 3 toxicity in six and
10%, respectively [11,12]. In the present study, not all
patients had a lumbar puncture for CSF analysis,
although all patients with only imaging available had
symptoms suggestive of LM. Furthermore, it is possible
that some patients with LM were missed when screening
the total ICI database because some could have had
asymptomatic LM that were invisible onMRI before ICI
therapy. Other drawbacks are inherent to the retrospec-
tive data collection (although the overview of patients
receiving ICI was prospectively collected), making
Response assessment in neuro-oncology (RANO)
response evaluation [14] not feasible. All patients could
be classified as having good or poor risk, but PD-L1
status (associated with outcome on ICI) was not available
for all. The included population was heterogeneous (e.g.
different previous treatments, driver mutations), making
comparisons across groups more difficult.
Trials specifically evaluating patients with LM are
often difficult to perform because the clinical condition
of these patients often deteriorates rapidly, and the
population is very heterogeneous. Currently, several
early-phase ICI trials for patients with LM are ongoing,
addressing PD-L1 inhibition (intravenous or intra-
thecal) with or without CTLA4 inhibition or radio-
therapy (Supplemental Table 3). Because first-line ICI
combined with chemotherapy proved superior to
chemotherapy alone [15], it would be interesting to
evaluate this combination in patients with LM.5. Conclusion
In conclusion, most patients with NSCLC having LM
do not benefit from ICI treatment, although some,
especially those in the NCCN LM good prognosis
group, can obtain a long survival.Conflicts of interest statement
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